Cargando...
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas
Most pituitary adenomas (PAs) are considered benign tumors, but approximately 0.2% can present metastasis and are classified as pituitary carcinomas (PCs). Refractory PAs lie between benign adenomas and true malignant PC and are defined as aggressive-invasive PAs characterized by a high Ki-67 index,...
Gardado en:
| Publicado en: | Front Endocrinol (Lausanne) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7761748/ https://ncbi.nlm.nih.gov/pubmed/33362722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2020.608422 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|